Clinical Acceleration Team Awards

OICR Clinical Translation (CT) advances cancer research toward meaningful clinical impact. It supports preclinical and early clinical studies that develop and validate new approaches to detect, treat and monitor cancer at its earliest and most actionable stages. Through close partnership with patients, clinicians and researchers, CT helps ensure that clinically relevant, high-potential innovations are positioned for patient and health care impact.

OICR is inviting applications for CT’s Clinical Acceleration Team Award (CATA) funding stream to support prospective clinical trials in which Molecular (Minimal) Residual Disease (MRD) assessment is a prespecified and integral component of the study design, and in which MRD results are explicitly linked to defined clinical decision points, management strategies or treatment adaptations. The intent of this funding opportunity is to support well-designed, decision-relevant studies that meaningfully advance MRD as a clinically actionable biomarker and contribute to the cumulative evidence required for future definitive evaluation and broader clinical adoption.